Cipla Ltd. is scheduled to report its earnings for the fourth quarter and monetary ended March 31, 2025, this week. The main pharmaceutical firm earlier introduced the date of the ends in a regulatory submitting to the inventory exchanges.
Listed below are all the important thing particulars it’s good to know concerning the This fall and FY25 outcomes of Cipla Ltd.
Cipla This fall Outcomes: Date And Dividend
Cipla Ltd. has introduced {that a} assembly of its Board of Administrators will probably be held on Tuesday, Might 13, 2025, to think about and approve necessary monetary issues. The Board will overview and approve the standalone and consolidated audited monetary outcomes of the corporate for the quarter and 12 months ended March 2025. Moreover, the Board will talk about and advocate the ultimate dividend for the monetary 12 months, if any.
Cipla This fall Outcomes: Buying and selling Window Closure
Cipla Ltd. has knowledgeable the inventory exchanges that, in compliance with SEBI guidelines, the buying and selling window for dealing within the firm’s securities has been closed from Tuesday, April 1, 2025. It’s going to stay shut till Thursday, Might 15, 2025, each days inclusive. The buying and selling restrictions will probably be relevant to designated individuals and their fast family, as per the SEBI pointers, to forestall insider buying and selling.
Cipla This fall Outcomes: Earnings Name
Cipla Ltd. has introduced that following the discharge of its monetary outcomes for the fourth quarter and monetary ended March 31, 2025, the corporate’s management workforce will host an earnings convention name on Might 13 at 4 p.m. Throughout the name, the administration will talk about the corporate’s monetary efficiency and handle questions from buyers and analysts.
The convention name timings in different areas are as follows:
-
1830 hrs SST/HKT
-
1130 hrs BST
-
, 0630 hrs hrs US ET
Listed below are the dial-in numbers for members to entry the decision:
Major Entry (India):
-
+91 22 6280 1562
-
+91 22 7115 8387
Toll-Free Numbers:
-
USA: 1-866-746-2133
-
UK: 0808-101-1573
-
Hong Kong: 800-964-448
-
Singapore: 800-101-2045
Cipla Q3 Outcomes
Cipla Ltd reported a 49.7% year-on-year enhance in consolidated web revenue for the quarter ended December 2024, reporting Rs 1,571 crore in comparison with Rs 1,049 crore in the identical interval of FY24. The corporate’s consolidated income from operations rose to Rs 7,072.97 crore within the December quarter, up from Rs 6,603.81 crore within the year-ago interval.
The corporate’s earnings earlier than curiosity, tax, depreciation, and amortisation (EBITDA) climbed 15.7% year-on-year to Rs 1,989 crore, in comparison with Rs 1,720 crore a 12 months in the past. The EBITDA margin additionally improved, increasing to twenty-eight.1% from 26.3% within the corresponding interval a 12 months in the past.
Cipla Share Worth Historical past
Previously 5 buying and selling periods, Cipla’s inventory has declined by 2.87%. It has fallen almost 1% within the final month. The pharma inventory has fallen 3.75% over the previous six months and 4% year-to-date. Nevertheless, within the final 12 months, the inventory has gained 3.77%.
Shares of Cipla Ltd. hit a 52-week excessive of Rs 1,702.05 apiece on Oct. 9, 2024, and a 52-week low of Rs 1,317.25 on Might 10, 2024.
Cipla shares have been buying and selling 0.8% down at Rs 1,468.00 apiece on the NSE on Monday, as of 9:40 a.m. This compares to a 2.54% rise in benchmark Nifty 50.
. Learn extra on Earnings by Newsstate24 Revenue.
